Abstract
The role of IFNα in chronic myeloid leukaemia patients who have achieved a deep molecular response (DMR) is still unknown. The study reported by Irani et al., which shows the prospective biological effects of the drug in combination with a second-generation tyrosine kinase inhibitor, pave the way for further clinical studies aimed at increasing the rate of DMR for a possible successful discontinuation. Commentary on: Irani et al. Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha. Br J Haematol 2023;202:1127-1136.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
